Shattuck Labs (STTK) Return on Capital Employed (2020 - 2026)
Shattuck Labs (STTK) reported Return on Capital Employed of 57.04% for Q1 2026, up 4051.0% year-over-year from 1.37% in Q1 2025, and up 1.85% quarter-over-quarter from 58.12% in Q4 2025.
Shattuck Labs (STTK) Return on Capital Employed (2020 - 2026) Analysis & Trends
Shattuck Labs (STTK) has 7 years of Return on Capital Employed data on file, last reported at 57.04% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 57.04%, up 4051.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 57.04% (up 4051.0% YoY), and the FY2025 annual result was 61.33%, up 789.0% from the prior year.
- Return on Capital Employed grew to 57.04% in Q1 2026 per STTK's latest filing, from 58.12% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 21.3% in Q1 2022 and troughed at 99.31% in Q2 2025.
- A 5-year average of 63.87% and a median of 65.17% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2026: Return on Capital Employed slumped 4598 bps in 2023, then jumped 4051 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 54.62% in 2022, then fell by 26 bps to 68.85% in 2023, then fell by 27 bps to 87.13% in 2024, then surged by 33 bps to 58.12% in 2025, then rose by 2 bps to 57.04% in 2026.
- Business Quant data shows STTK's Return on Capital Employed at 57.04% in Q1 2026, 58.12% in Q4 2025, and 75.02% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Shattuck Labs | 190.32 Mn | 190.32 Mn | - | -57.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.04% |
| Dec 31, 2025 | -58.12% |
| Sep 30, 2025 | -75.02% |
| Jun 30, 2025 | -99.31% |
| Mar 31, 2025 | -97.55% |
| Dec 31, 2024 | -87.13% |
| Sep 30, 2024 | -74.12% |
| Jun 30, 2024 | -73.95% |
| Mar 31, 2024 | -65.17% |
| Dec 31, 2023 | -68.85% |
| Sep 30, 2023 | -77.08% |
| Jun 30, 2023 | -62.49% |
| Mar 31, 2023 | -57.45% |
| Dec 31, 2022 | -54.62% |
| Sep 30, 2022 | -31.10% |
| Jun 30, 2022 | -25.42% |
| Mar 31, 2022 | -21.30% |
| Dec 31, 2021 | -16.17% |
| Sep 30, 2021 | -22.37% |
| Jun 30, 2021 | -19.28% |